



Healthcare Weekly News and Deals – November 21st, 2025

1. Abbott (NYSE: ABT) to acquire Exact Sciences (NASDAQ: EXAS) in \$21 Billion All-Cash Deal to Expand Global Cancer Screening and Precision Oncology Diagnostics Portfolio

This acquisition grants Abbott immediate access to advanced cancer diagnostic technologies and a robust product lineup that includes Cologuard®, Oncotype DX®, and innovative liquid biopsy solutions for early detection and monitoring. Exact Sciences generates over \$3 billion in annual revenue, with high-teens organic growth, and its diagnostic reach will substantially boost Abbott's global impact. The deal, which includes assumption of \$1.8 billion in debt, is expected to close mid-2026 pending regulatory and shareholder approvals and aligns two leaders to accelerate innovation and make next-generation cancer care more widely accessible. ([Link](#))

2. Merck (NYSE: MRK) to acquire Cidara Therapeutics (NASDAQ: CDTX) for \$9.2 Billion, Gaining Late-Phase Antiviral CD388 for Influenza Prevention

Cidara Therapeutics' lead drug candidate, CD388, is a potentially first-in-class, long-acting agent for preventing both influenza A and B, currently in Phase 3 trials and supported by robust efficacy data from Phase 2b studies. The drug has received Breakthrough Therapy and Fast Track designations from the FDA, expediting regulatory review for high-risk patients. The deal, structured as an all-cash tender offer, has been unanimously approved by both companies' boards and awaits shareholder and regulatory clearance, with completion targeted for Q1 2026. Merck expects the acquisition to strengthen its global infectious disease pipeline. ([Link](#))

3. GE Healthcare (NASDAQ: GEHC) to acquire Intelera in \$2.3 Billion Deal to Expand Cloud-Enabled and AI-Driven Imaging Platform for Radiology, Cardiology, and Outpatient Enterprise Markets

Intelera's expertise in cloud-based imaging and AI workflow automation will help GE HealthCare extend its digital solutions for radiology and cardiology beyond hospital settings, supporting healthcare providers through more efficient, data-driven care. The deal will add \$270 million in annual revenue, with nearly 90% coming from recurring sources. In the combined company, Intelera's low-double-digit revenue growth and adjusted EBITDA margins exceeding 30% are expected to accelerate, while enhancing productivity and patient outcomes worldwide. GE HealthCare plans to triple cloud-enabled offerings by 2028 via this strategic acquisition, modernizing workflows for outpatient and ambulatory care to streamline operations and unify data. Backed by GE HealthCare's global reach and financial flexibility, the integration aims to drive significant top-line growth and recurring revenue from expanded SaaS and AI-driven imaging platforms. ([Link](#))

4. **Solventum (NYSE: SOLV) to acquire Acera Surgical for \$725 Million Plus Milestone Payments, Expanding Advanced Wound Care Portfolio with Synthetic Tissue Matrices Technology**

The acquisition brings Acera Surgical's proprietary electrospinning platform and Restrata® products for complex wound treatment into Solventum's fast-growing MedSurg segment, targeting an acute care market segment valued at \$900 million. Solventum plans to leverage its global reach, specialized sales force, and clinical partnerships to drive Restrata® adoption and generate commercial synergies. The deal, financed entirely with cash on hand, is expected to close in the first half of 2026 and adds \$90 million in projected 2025 sales from Acera. The acquisition is initially slightly dilutive to adjusted EPS, turning accretive in 2027. ([Link](#))

5. **Halozyme Therapeutics (NASDAQ: HALO) completes \$750 Million Acquisition of Elektrofi, Unlocks Hypercon™ Technology for High-Concentration Biologics and Expands Drug Delivery Offerings**

The acquisition will diversify Halozyme Therapeutics drug delivery platform, enabling integration of Hypercon™ technology capable of creating high-concentration protein formulations that streamline administration and support smaller injection volumes. This strengthens its pipeline, as two partner programs based on this technology are projected to enter clinical development by 2026, potentially yielding up to \$275 million in development and commercial milestone payments before royalty revenues begin in 2030. Halozyme anticipates less than 5% EPS dilution in the medium term, with the transaction funded from existing cash and credit resources. ([Link](#))

6. **Nanox Imaging (NASDAQ: NNOX) to acquire VasoHealthcare IT from Vaso Corporation (OTCQX: VASO) for Up to \$800,000 to Accelerate U.S. Rollout of FDA-Cleared AI Medical Imaging Solutions**

Nanox's acquisition will merge VasoHealthcare IT's operational and customer-support infrastructure with Nanox.AI's solutions for analyzing routine CT scans, targeting faster adoption and more efficient U.S. deployment of AI-driven diagnostic technology. The deal includes a \$200,000 cash payment at closing and up to \$600,000 in performance-based earnouts over two years, contingent upon revenue retention from existing clients. The combination is expected to enhance Nanox's commercial reach by leveraging VasoHealthcare IT's expertise and established healthcare provider relationships, supporting the company's growth strategy in early disease detection and workflow optimization across U.S. healthcare facilities. ([Link](#))

7. **RadNet (NASDAQ: RDNT) acquires River Radiology, Strengthening New York Imaging Network and Expanding Lenox Hill Radiology's Geographic Reach**

River Radiology provides Kingston and the Hudson Valley region with high-quality diagnostic imaging, including MRI, CT scans, ultrasounds, PET/CT, and 3D mammography. Known for its commitment to patient care, accurate reports, and compassionate service, it operates with extended weekday hours for patient convenience. The practice was originally established as Ulster Radiologic Associates and is locally recognized for individualized care and legacy in medical imaging excellence. Its presence in the area offers access to innovative screening technology and comprehensive radiology options for a wide range of referring providers and patients. ([Link](#))

8. ClearPoint Neuro (NASDAQ: CLPT) completes acquisition of IRRAS, Bringing IRRFlow System and Expanding Neurocritical Care and Drug Delivery Capabilities

The transaction is projected to immediately expand ClearPoint Neuro's reach in neurocritical care, adding more than 50 clinical customers, a broader sales force, and new patent families while integrating the IRRFlow system for advanced treatment of intracranial bleeding. IRRFlow's published clinical benefits include reduced catheter occlusions, lower infection rates, and shorter treatment times, potentially decreasing hospital costs. With the combined entity targeting \$54–60 million in 2026 revenue, leadership anticipates operational synergies, greater commercial leverage, and an enhanced pipeline for cell, gene, and drug delivery innovations. ([Link](#))

9. Reliant Healthcare and Care Fusion Rx Merge to Transform U.S. Infusion Therapy with Expanded Home and Ambulatory Service Platform

Reliant Healthcare, established in 2008, provides home infusion and ambulatory infusion center services in Louisiana, Texas, and Oklahoma, with 14 centers and multiple specialty pharmacies. Care Fusion Rx, founded in 2020 and based in California, focuses on complex therapies—particularly advanced immunoglobulin treatments—on the West Coast. The merged company will offer chronic disease, neurology, immunology, oncology, rheumatology, and gastroenterology therapies to thousands of patients locally and nationally. It will invest in new facilities, expand home infusion territories, and pursue strategic growth in high-potential and underserved U.S. markets, guided by a veteran leadership team. ([Link](#))

10. ARC Health Partners acquires Clarity Counselling Center, Adding Wilmington-Based Practice to 23-Group National Network and Expanding North Carolina Reach with Backing from Thurston Group

Clarity Counselling Center, known for its outpatient therapy services and innovative relationship counselling programs for all ages, will retain clinical leadership after joining ARC Health Partners. The acquisition broadens ARC Health's platform to 92 locations and over 1,300 providers in 21 states and enhances its service capacity in North Carolina, complementing partners in the Raleigh-Durham area. Clarity's local reputation for clinical excellence and community impact made it an attractive addition to ARC's provider-centric, equity-partner model. The deal signals ARC Health's continued pursuit of growth through clinician-led partnerships across the country. ([Link](#))

11. MRO acquires Clinetic, via its financial sponsors Healthworx and Parthenon Capital Partners to Transform Patient Recruitment and Streamline Clinical Trial Enrollment with Scalable AI-EHR Integration

Clinetic's AI-driven recruitment platform connects securely to hospital electronic health record (EHR) systems, providing direct real-time access to robust clinical data and enabling precise patient matching for hundreds of clinical trials. With a data reach spanning more than 15 million patients nationwide, Clinetic boosts MRO's ability to support over 2,000 hospital and health system partners with efficient, scalable participant identification and study cohort building. The integration will power the Q-Centrix Research Network, reduce manual clinical trial staff workload, improve data accuracy, and accelerate research timelines while supplying life sciences clients with high-quality, actionable datasets. ([Link](#))

12. OhioHealth to acquire Fairfield Medical Center, Expanding Network to 17th Hospital

OhioHealth, a Columbus-based health system, is finalizing plans to acquire Fairfield Medical Center, an independent hospital in Lancaster, which will become its 17th member hospital upon completion. The acquisition follows the endorsement of a merger by both health systems' boards in September 2024, after signing a non-binding letter of intent that month to explore a partnership. Both parties are proceeding with finalization, including completing necessary government filings, as confirmed by spokespersons from OhioHealth and Fairfield Medical Center. The merger aims to enhance care delivery in Fairfield County and surrounding areas, addressing the needs of a growing and aging population through increased collaboration. Key benefits include greater efficiencies, enhanced quality measures, and access to resources from a larger health system, building on OhioHealth's recent expansions such as adding Morrow County Hospital in January 2025 and projects like the Riverside Methodist Hospital Women's Center opening in 2027. Pending regulatory approvals, the deal is expected to close in 2026, with no financial terms disclosed. ([Link](#))

13. WVU Health System to acquire Independence Health System, Growing to 30-Hospital Network with \$800 Million Investment Commitment

Morgantown-based WVU Health System will acquire Greensburg's Independence Health System, including five hospitals, physician groups, and subsidiaries, rebranding them under WVU Medicine to expand access to advanced care across regions. WVU pledges \$800 million over five years for facility modernization and improvements, aiming to integrate operations and enhance service quality. The acquisition will grow WVU's network to 30 hospitals, fostering collaboration to address healthcare needs in Pennsylvania and surrounding areas. Leadership from both systems emphasized the partnership's potential to improve patient outcomes through shared resources and expertise. Closing is anticipated in fall 2026, pending regulatory approvals, with no specific financial terms for the acquisition disclosed beyond the investment commitment. This strategic move aligns with WVU's expansion goals, building on its nonprofit status to deliver comprehensive care. ([Link](#))

Venture and Other News

1. Function Health raises \$298 Million Series B led by Redpoint Ventures and a16z at \$2.5 Billion Valuation and Launches Medical Intelligence Lab

Function Health secured \$298 million in Series B funding at a \$2.5 billion valuation, led by Redpoint Ventures with participation from a16z, establishing it as a leader in proactive health management. The company offers comprehensive lab testing, body scans, and health data consolidation to detect over 1,000 conditions early through more than 100 biomarkers, focusing on health optimization and intelligence. The funding will expand U.S. locations, develop AI health features, lower annual membership pricing, and support the newly launched Medical Intelligence Lab for advancing health and longevity research. Function aims to set a new standard in preventive care, making advanced diagnostics more accessible and affordable. This round highlights investor confidence in Function's model to transform healthcare through data-driven insights and early intervention. ([Link](#))

2. Solve Therapeutics raises \$120 Million financing led by Yosemite, Abingworth, and Ally Bridge Group to advance antibody drug conjugates.

Solve Therapeutics secured \$120 million in an oversubscribed financing round on November 17, 2025, with no specific series designated, bringing its total capital raised to \$321 million. Lead investors included Yosemite, Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co., SymBiosis, Alexandria Venture Investments, AyurMaya Capital Management, DC Global Ventures, General Atlantic, and Citadel's Surveyor Capital. The funds will support two clinical-stage antibody-drug conjugates (ADCs) and expand the proprietary CloakLink linker platform, which enhances ADC stability and reduces payload hydrophobicity across various drug-to-antibody ratios. Boston-based Solve focuses on developing best-in-class ADCs for targeted cancer therapies, advancing its oncology pipeline through clinical progression and platform growth. This raise underscores strong investor support for Solve's innovative approach to improving ADC efficacy and safety in cancer treatment. ([Link](#))

3. Aspen Neuroscience raises \$115 Million Series C led by OrbiMed, ARCH Venture Partners, and Frazier Life Sciences to advance Parkinson's disease cell therapy.

Aspen Neuroscience raised \$115 million in a Series C financing round on November 20, 2025, to propel its neurodegenerative disorder programs. Investors comprised OrbiMed, ARCH Venture Partners, Frazier Life Sciences, Revelation Partners, Medical Excellence Capital, S32, Axon Ventures, LYFE Capital, LifeForce Capital, Gilead's Kite Pharma, Balyasny Asset Management, Cormorant Asset Management, Prebys Ventures, and others. The proceeds will advance the phase 1/2 study of ANPD001, an autologous therapy that converts patients' skin cells into neurons for brain transplantation to treat Parkinson's disease, with 14 patients dosed so far and phase 3 planned for next year. San Diego-based Aspen specializes in personalized regenerative medicine, leveraging this funding to accelerate its Parkinson's program and cell therapy pipeline. The raise reflects confidence in Aspen's innovative approach to addressing unmet needs in neurological disorders through patient-specific treatments ([Link](#))

4. **Profluent raises \$106 Million led by Altimeter Capital, Bezos Expeditions, and Spark Capital to advance AI-driven protein design.**

Profluent raised \$106 million in a financing round on November 19, 2025, with no series specified, bringing its total funding to \$150 million. Investors included Altimeter Capital, Bezos Expeditions, Spark Capital, Insight Partners, and Air Street Capital. The funds will support efforts to make biology programmable through AI-driven protein design, scaling frontier AI models for various applications. The company has partnerships with the Rett Syndrome Research Trust for novel base editors and with Revvity to accelerate gene editing therapies. Berkeley-based Profluent specializes in generative AI for creating novel proteins, aiming to revolutionize therapeutics and biotech.

5. **AI Proteins raises \$41.5 Million Series A led by Mission BioCapital, Santé Ventures, and Cobro Ventures to advance AI-designed mini protein therapeutics.**

AI Proteins will use the funding to industrialize its generative AI and synthetic biology-powered platform for designing de novo miniproteins, which have proven functional across more than 150 targets and multiple in vivo studies. The company is launching a “hub-and-spoke” LLC business structure to protect technology progress and spin out asset-focused subsidiaries. Beyond internal programs, AI Proteins partners with Bristol Myers Squibb in a \$400 million research and option deal, and is exploring applications in diagnostics, agriculture, and reagents. Lightchain Capital and Cobro Ventures also participated, further supporting operational scalability and innovation. This Series A round enables rapid, scalable discovery of more effective, stable, and precisely targeted therapeutics across various fields. ([Link](#))

6. **Nest Health raises \$22.5 Million Series A Led by Socium Ventures, Amboy Street Ventures, and Impact America Fund for Medicaid Whole-Family In-Home Care Expansion**

Nest Health will utilize the new funding to expand its AI-powered, in-home medical, behavioral, and social care for Medicaid families, strengthening clinical offerings and extending reach into new regions. The company’s model has yielded outcomes such as 60% ER visit reduction, doubled vaccination rates, high Net Promoter Scores, and substantial ROI for payer partners. Current operations in Louisiana and Arizona continue to demonstrate measurable health improvements, especially in underserved areas, supporting their national growth ambition. The round includes participation from Hopelab, University Growth Fund, Luminary Impact Fund, and Blue Cross Blue Shield of Arizona Health Choice. ([Link](#))

7. **Lumia raises \$7 Million led by J2 Ventures and BonAngels Venture Partners for Lumia 2 smart earrings launch.**

Lumia’s new earrings, available as hoops, cuffs, and studs in multiple finishes, use infrared sensors in the PreciseLight Core to measure arterial blood flow at the ear—enabling insights on sleep, temperature, menstrual cycles, and daily readiness with greater accuracy than wrist wearables. The SwitchBack tech lets users attach the smart Core to any push-back earring, while the cuff version requires no piercing. Each earring weighs less than a gram, offers five to eight days of battery life, and was validated at Johns Hopkins, Duke, and Harvard. Lumia has \$17.2 million total funding and holds 11 patents or applications. This raise supports the launch and broader adoption of Lumia 2 for wellness monitoring. ([Link](#))